Quick Answer
Sonoma Pharmaceuticals, Inc. reported Net Income of -$3.46 million for fiscal year 2025.
Sonoma Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$3.46M | +28.5% |
| 2024 | -$4.83M | +6.1% |
| 2023 | -$5.15M | -1.3% |
| 2022 | -$5.09M | -28.8% |
| 2021 | -$3.95M | -19.4% |
| 2020 | -$3.31M | +72.0% |
| 2019 | -$11.80M | +17.7% |
| 2018 | -$14.33M | -254.5% |
| 2017 | $9.27M | +191.3% |
| 2016 | -$10.16M | -23.9% |
| 2015 | -$8.20M | -319.6% |
| 2014 | $3.73M | +168.8% |
| 2013 | -$5.43M | +25.9% |
| 2012 | -$7.33M | +7.8% |
| 2011 | -$7.95M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$819.0K | +11.7% | -53.4% |
| September 30, 2025 | -$534.0K | +12.5% | +57.0% |
| June 30, 2025 | -$1.24M | -8.6% | -33.7% |
| December 31, 2024 | -$928.0K | -7.2% | -52.1% |
| September 30, 2024 | -$610.0K | +58.9% | +46.6% |
| June 30, 2024 | -$1.14M | +19.4% | -32.0% |
| December 31, 2023 | -$866.0K | +55.3% | +41.6% |
| September 30, 2023 | -$1.48M | -45.9% | -4.7% |
- Sonoma Pharmaceuticals, Inc. showed an increase of +28.5% in Net Income compared to the prior fiscal year.
- Over the 2011–2025 period, Sonoma Pharmaceuticals, Inc.’s net income has grown by 56.5% (from -$7.95 million to -$3.46 million).
- The most recent figure is from Sonoma Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: